SGLT-2 inhibitors and GLP-1 receptor agonists for Type 2 diabetes

被引：0
|
作者：
Davila, Esteban [1 ]
Mccormack, James [2 ]
机构：
[1] New York City Hlth Hosp Kings Cty, Dept Emergency Med, 451 Clarkson Ave, Brooklyn, NY 11203 USA
[2] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada
来源：
ACADEMIC EMERGENCY MEDICINE | 2024年 / 31卷 / 04期
关键词：
diabetes; GLP-1 receptor agonist; metformin; SGLT-2; inhibitor;
D O I：
10.1111/acem.14895
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
[No abstract available]
引用
收藏
页码：408 / 411
页数：4
相关论文
共 50 条
  • [21] Exploring nontraditional cardiorenal advantages of SGLT-2 inhibitors and GLP-1 receptor agonists
    Chen, Jia-Jin
    Lee, Tao-Han
    Yang, Huang-Yu
    KIDNEY INTERNATIONAL, 2024, 105 (03) : 442 - 444
  • [22] Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2019, 61 (1566): : 26 - 28
  • [23] Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT-2 inhibitors and GLP-1 receptor agonists
    Bonaventura, A.
    Carbone, S.
    Dixon, D. L.
    Abbate, A.
    Montecucco, F.
    JOURNAL OF INTERNAL MEDICINE, 2019, 286 (01) : 16 - 31
  • [24] Cardio-Renal Benefits of GLP-1 Receptor Agonists vs. SGLT-2 Inhibitors in Type 2 Diabetes: Are They Juxtaposed?
    Singh, Awadhesh Kumar
    Shah, Viral N.
    CLINICAL DIABETOLOGY, 2022, 11 (04): : 215 - 221
  • [25] Cardiovascular outcomes of patients with type 2 diabetes treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real life
    Fadini, G.
    Longato, E.
    Di Camillo, B.
    Sparacino, G.
    Gubian, L.
    Avogaro, A.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S61 - S61
  • [26] Efficacy of GLP-1 receptor agonists and SGLT-2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients
    Azhie, A.
    Gupta, S.
    Misra, S.
    Chen, S.
    Meerasa, A.
    Dash, S.
    Woo, M.
    Bhat, M.
    TRANSPLANTATION, 2022, 106 (8S) : 103 - 103
  • [27] Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study
    Lugner, Moa
    Sattar, Naveed
    Miftaraj, Mervete
    Ekelund, Jan
    Franzen, Stefan
    Svensson, Ann-Marie
    Eliasson, Bjoern
    CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
  • [28] Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study
    Moa Lugner
    Naveed Sattar
    Mervete Miftaraj
    Jan Ekelund
    Stefan Franzén
    Ann-Marie Svensson
    Björn Eliasson
    Cardiovascular Diabetology, 20
  • [29] Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists
    Khedagi, Apurva
    Hoke, Cara
    Kelsey, Michelle
    Coviello, Andrea
    Jones, W. Schuyler
    Jackson II, Larry R.
    Patel, Manesh R.
    McGarrah, Rob W.
    Pagidipati, Neha J.
    Shah, Nishant P.
    AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2023, 13
  • [30] The protective effects of SGLT-2 inhibitors, GLP-1 receptor agonists, and RAAS blockers against renal injury in patients with type 2 diabetes
    Zengguang Kuang
    Ningning Hou
    Chengxia Kan
    Fang Han
    Hongyan Qiu
    Xiaodong Sun
    International Urology and Nephrology, 2023, 55 : 617 - 629
12345